实验室单品
laboratory item
相关产品
CAS:1330261-26-1|Prothionamide-d5
- 产品货号:DT2025062062
- 发布时间:2025-06-09
- 产品CAS :1330261-26-1
- 产品规格:mg(更多包装需求请咨询客服)
- 产品纯度:≥98%
- 产品货期:现货下单后48小时内发货,定制产品4-8周。
- 运输条件:顺丰常规运输
产品详情
货号:DT2025062062
CAS:1330261-26-1
规格:mg(更多包装需求请咨询客服)
纯度:≥98%
生产商:试剂家
生物活性:Prothionamide-d5 is deuterium labeled Prothionamide (HY-B0306). Prothionamide is an orally active thioamide antibacterial agent. Prothionamide is a substrate of OCT1 with a Km value of 805.8 μM. Prothionamide reacts with NAD to form a covalent adduct, with the adduct being a tight-binding inhibitor of Mycobacterium tuberculosis and Mycobacterium leprae InhA. Prothionamide can effectively inhibit the growth of Mycobacterium tuberculosis (MIC = ~0.5 µg/mL) and Mycobacterium leprae. Prothionamide is used in the research of tuberculosis and leprosy[1][2][3][4][5].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Prothionamide-d5 相关抗体:
MRP2 Antibody
Elongation factor 2 Antibody (YA962)
Elongation factor 2 Antibody (YA964)
PU.1/SPI1 Antibody (YA1116)
Sulfadimidine Antibody (YA906)
Elongation factor 2 Antibody (YA963)
Anthrax Protective gen Antibody (YA1060)
Elongation factor 1 gamma Antibody (YA2004)
Pulmonary Surfactant Associated Protein D Antibody (YA2107)
Cathelicidin Antibody (YA2380)
Elongation Factor Ts Antibody (YA2524)
Elongation Factor 1A2 Antibody (YA2879)
BPI Antibody (YA3068)
MetRS Antibody (YA3196)
分子量:185.30
Formula:C9H7D5N2S
CAS 号:1330261-26-1
非标记 CAS:14222-60-7
中文名称:丙硫异烟胺-d5; 扑痨硫胺-d5
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Wang F, et al. Mechanism of thioamide drug action against tuberculosis and leprosy.J Exp Med. 2007 Jan 22;204(1):73-8.
[Content Brief]
[2]. Fajardo TT, et al. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am J Trop Med Hyg. 2006 Mar;74(3):457-61.
[Content Brief]
[3]. Parvez MM, et al. Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00512-18.
[Content Brief]
[4]. Grosset , et al. The role of low dosage prothionamide with and without 4, 4'-diaminio dipheimyl sulphone for use with isoniazld in the treatment of experimental mouse tuberculosis. Tubercle, 1982, 63(1): 37-43.
[5]. Krasavin M, et al. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis. Eur J Med Chem. 2018 Sep 5;157:1115-1126.
[Content Brief]
在线留言
欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。